Researchers from Sungkyunkwan University School of Medicine Discuss Findings in Colon Cancer [Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial]

Press/Media: Press / Media

Period2025 Oct 30

Media coverage

1

Media coverage

  • TitleResearchers from Sungkyunkwan University School of Medicine Discuss Findings in Colon Cancer [Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial]
    Media name/outletImmunotherapy Daily
    Country/TerritoryUnited States
    Date25/10/30
    PersonsSoohyeon Lee
View all 1
View less